Niklas Krupka
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Woelfel S, Dütschler J, König M, Dulovic A, Graf N, Junker D, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Koller S, Wyss J, Krupka N, Oberholzer M, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Albrich W, Friedrich M, Schneiderhan-Marra N, Misselwitz B, Korte W, Bürgi J, Brand S. STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2023; 58:678-691.
12.08.2023STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
12.08.2023Aliment Pharmacol Ther 2023; 58:678-691
Woelfel Simon, Dütschler Joel, König Marius, Dulovic Alex, Graf Nicole, Junker Daniel, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Koller Seraina, Wyss Jacqueline, Krupka Niklas, Oberholzer Melanie, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Schneiderhan-Marra Nicole, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, STAR SIGN Study Investigators, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. Aliment Pharmacol Ther 2022; 57:103-116.
28.10.2022Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
28.10.2022Aliment Pharmacol Ther 2022; 57:103-116
Woelfel Simon, Dütschler Joel, König Marius, Graf Nicole, Oikonomou Vasileios, Krieger-Grübel Claudia, Truniger Samuel, Franke Annett, Eckhold Annika, Forsch Kristina, Wyss Jacqueline, Krupka Niklas, Albrich Werner, Frei Nicola Fabian, Geissler Nora, Schaub Peter, STAR SIGN Study Investigators, Friedrich Matthias, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan
Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022; 15:17562848221074188.
09.02.2022Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.
09.02.2022Therap Adv Gastroenterol 2022; 15:17562848221074188
Perrig Kathrin, Krupka Niklas, Jordi Sebastian Bruno Ulrich, Rossel Jean-Benoit, Biedermann Luc, Greuter Thomas, Schreiner Philipp, Vavricka Stephan R, Juillerat Pascal, Burri Emanuel, Zimmermann Dorothee, Maillard Michel H, Sulz Michael Christian, Brand Stephan, Rogler Gerhard, Misselwitz Benjamin